双环醇治疗慢性乙型肝炎临床研究  

Clinical analysis of treating chronic hepatitis B with bicycolol

作　　者：沈玲[1] 赵伟[1] 方之勋[1] 李定坤[1] 杨毅军[1] 詹容娥[1] 钟备[1] 徐乾[1] 文睿[1] 舒伟平[1] 

机构地区：[1]东南大学医学院附属南京市第二医院传染病教研室,江苏南京210003

出　　处：《世界感染杂志》2006年第1期67-69,共3页World Journal of Infection

摘　　要：目的评估双环醇治疗慢性乙型肝炎的疗效和安全性。方法慢性乙型肝炎病人服用双环醇25mg，3次／d，共24wk。结果经双环醇治．疗后，临床症状有较大程度的改善，ALT和AST的复常率分别为53．19％和53．19％，停药12wk后分别为72．34％和74．47％。治疗结束和停药12wk后，血清HBeAg阴转率分别为23．40％和27．66％，HBeAg／HBeAb血清转换率分别为8．51％和12．77％，HBV DNA阴转率分别为10．64％和17．02％；治疗前ALT〉200U／L者，HBeAg阴转率显著高于ALT〈60U／L者。病人在治疗期间未出现明显不良反应。结论双环醇对改善慢乙肝病人临床症状和降低转氨酶有很好的疗效，不良反应少，病人耐受性好，有一定的抗病毒作用．Objective To evaluate the efficacy and safety of bicycolol in the treatment of patients with chronic hepatitis B （CHB）. Methods The patients with CHB were treated by bicycolol （25rag. rid. for 24wk） Results The clinical symptom significantly improved after treated with bicycolol. ALT and AST normalized rate was 53.19% and 53.19%; and was 72.34% and 74.47% 12 wk after treatment, respectively. When treatment was over and 12 after it, negative rate of HBeAg reached 23.40% and 27.66%; sero-conversion rate of HBeAg/HBeAb reached 8.51% and 12.77%, and negative rate of sere HBVDNA reached 10.64% and 17,02%, respectively. Negative rate of HBeAg was significantly higher in the group with ALT level 〉 200U/L than that with AL T level =60U/L, No significant side effect was documented during the treatment. Conclusions bicycolol showed satisfied efficacy and safety in decreasing sera ALT and improve symptoms, It was well tolerated and showed anti-viral effects.

关 键 词：双环醇 乙型肝炎 慢性活动性 临床试验 

分 类 号：R512.62[医药卫生—内科学]